Bio-Path Holdings Inc (NASDAQ:BPTH) stock price target upped to $0.75, released a report earlier today by Zacks Investment Research
- Updated: March 20, 2017
Bio-Path Holdings Inc (NASDAQ:BPTH) had its target bumped up to $0.75 by Zacks Investment Research in a report released 03/20/2017. The new target price indicates a possible downside of -0.10% from the company's previous stock price.
Only yesterday Bio-Path Holdings Inc (NASDAQ:BPTH) traded 8.06% higher at $0.83. Bio-Path Holdings Inc’s 50-day average is $0.87 and its two hundred day average is $1.14. With the last close down -27.10% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same time period. 174,606 shares of the stock traded hands, up from an average trading volume of 158,303
See Chart Below
Bio-Path Holdings Inc has a 52 week low of $0.70 and a 52 week high of $3.19 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 1 broker has issued a research note on the company. The average stock price target is $5.00 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Bio-Path Holdings Inc (NASDAQ:BPTH)
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.